Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to cut short sickle cell pain attacks

NCT ID NCT06699849

Symptom relief Sponsor: CSL Behring Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests an investigational drug called CSL889 in 70 adults and adolescents with sickle cell disease who are having a painful vaso-occlusive crisis. The goal is to see if the drug can safely shorten the crisis and reduce the need for strong pain medicines. Participants will receive either CSL889 or a placebo by IV, and researchers will monitor how quickly the pain resolves and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At the time of informed consent: * 18 years of age (adults); or * 12 to less than (\<) 18 years of age (adolescents, where approved and when enrollment for adolescents has been opened by the sponsor, with the endorsement of the Independent Data Monitoring Committee \[IDMC\]) * Diagnosed with SCD (any genotype). * Presented at the study site with a new acute VOC necessitating treatment with parenteral opioids. Exclusion Criteria: * VOC pain onset greater than (\>) 72 hours before administration of first parenteral opioid. * Must not have a history of \> 5 VOCs requiring hospital admission in the past 6 months; or signs and / or symptoms of ACS; or new neurological symptoms suggestive of acute stroke or transient ischemic attack; or any stage (acute kidney injury) AKI; or been discharged from inpatient hospital admission for VOC or other vaso-occlusive event within 14 days before the current presentation. * Serum hemoglobin \< 6 g/dL, serum ferritin ≥ 2000 ng/mL, receiving an approved medication for SCD that has not been on a stable, well-tolerated regimen, currently taking methadone or buprenorphine.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sickle cell disease vaso-occlusive crisis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute chest syndrome acute kidney injury sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sickle cell disease vaso-occlusive crisis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    26 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Arthur M. Blank Hospital-Children's Healthcare of Atlanta

    RECRUITING

    Atlanta, Georgia, 30329, United States

  • Baskent University School of Medicine

    RECRUITING

    Adana, 01120, Turkey (Türkiye)

  • Detroit Medical Center

    RECRUITING

    Detroit, Michigan, 48201, United States

  • East Carolina University

    RECRUITING

    Greenville, North Carolina, 27834, United States

  • Golisano Children's Hospital

    RECRUITING

    Fort Myers, Florida, 33908, United States

  • Guy's Hospital

    RECRUITING

    London, SE1 9RT, United Kingdom

  • Hacettepe Universitesi

    NOT_YET_RECRUITING

    Ankara, 06230, Turkey (Türkiye)

  • Henry Ford Health System

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Istanbul Universitesi

    NOT_YET_RECRUITING

    Istanbul, 34093, Turkey (Türkiye)

  • Jacobi Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

  • Medical Park Mersin Hospital

    RECRUITING

    Mezitli-Mersin, 33200, Turkey (Türkiye)

  • Mount Sinai Medical Center

    RECRUITING

    New York, New York, 10029, United States

  • St. Louis Children's Hospital

    RECRUITING

    St Louis, Missouri, 63110, United States

  • The Foundation for Sickle Cell Disease

    RECRUITING

    Hollywood, Florida, 33023-6703, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43085, United States

  • Univ. of California, San Francisco Health Care

    RECRUITING

    Oakland, California, 94609, United States

  • University of California Irvine

    NOT_YET_RECRUITING

    Orange, California, 92868, United States

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45267, United States

  • University of Illinois at Chicago

    RECRUITING

    Chicago, Illinois, 60612, United States

  • University of Louisville Hospital

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • University of Maryland

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • University of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23298, United States

  • Özel Acibadem Adana Hastanesi

    NOT_YET_RECRUITING

    Seyhan, 01130, Turkey (Türkiye)

  • Özel Acibadem Adana Hastanesi

    RECRUITING

    Seyhan/Adana, 01130, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.